February 6, 2025
California-Based HealthTech Startup Miist Therapeutics raises $7M in seed funding to Advance Inhaled Drug Delivery Technology
Alameda, California, United States, –
Miist Therapeutics, a pulmonary drug delivery system and digital platform developer, has raised $7 million in a seed funding round. Announced on February 5, 2025, The funding round saw participation from investors including 1517 Fund, California Innovation Fund, Entrepreneur First, Freeflow Ventures, and Refactor. The funds will be used to accelerate the company’s efforts in smoking cessation and other therapeutic applications.
About Miist Therapeutics
Founded in 2019 by Dalton Signor, Miist Therapeutics is pioneering a physics-based approach to inhaled drug delivery, aiming to enhance the efficacy and speed of medication absorption. The company is currently focusing on two primary programs: a smoking cessation therapy and a migraine treatment. With smoking-related illnesses remaining a major public health concern, MIIST's technology seeks to provide instant relief and reduce dependency on traditional tobacco products.
Purpose of financing
The newly secured funding will be used to advance clinical trials for its lead product, MST-01, designed to help individuals quit smoking by providing a rapid-acting alternative. The company also plans to expand research on MST-02, a novel treatment for migraine patients. Additionally, Miist intends to invest in scaling its proprietary inhalation technology and further developing its digital platform to optimize drug delivery and patient monitoring.
CEO's Insights
Dalton Signor, CEO and Co-founder of Miist Therapeutics, shared his thoughts on the impact of their technology:
“Many existing treatments today, especially for conditions like migraines, rely on oral medications that take too long to take effect,” said Signor. “Patients suffering from severe migraines or smoking dependence need rapid relief, and that’s exactly what our technology is designed to deliver.”
Investor Perspective
Zal Bilimoria, General Partner at Refactor, highlighted the company’s progress, stating:
“The Miist team has executed across every phase of development, from early technical R&D through human clinical studies. With these Phase 1 trial results validating the rapid action of their peripheral lung delivery and multiple active programs already in development, there is a real opportunity here to set a new treatment standard for many conditions.”
Conclusion
With this funding, Miist Therapeutics aims to bring its inhaled drug delivery solutions closer to commercialization, potentially benefiting millions of patients worldwide who need faster-acting treatments.
For updates, visit Miist Therapeutics on Linkedin.